ARBER D A, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127: 2391-2405.
[2]
WANG Z Y, CHEN Z. Acute promyelocytic leukemia: From highly fatal to highly curable[J]. Blood, 2008, 111: 2505-2515.
[3]
LO-COCO F, CICCONI L, BRECCIA M. Current standard treatment of adult acute promyelocytic leukaemia[J]. British Journal of Haematology, 2016, 172: 841-854.
[4]
CHEN L, ZHU H M, LI Y, et al. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)[J]. Proceedings of the National Academy of Sciences of the United States of Americal, 2021, 118: e2020382118.
[5]
SANZ M A, LO C F, MARTIN G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups[J]. Blood, 2000, 96: 1247-1253.
[6]
TAN Y, WANG X L, SONG H, et al. A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia[J/OL]. Blood, 2020: 2020005698 [2021-02-05]. https:∥doi.org/10.1182/blood.2020005698.